Stem cell-based test predicts leukemia patients’ response to therapy to tailor treatment – Medical Xpress
Medical Xpress |
Stem cell-based test predicts leukemia patients’ response to therapy to tailor treatment
Medical Xpress The new biomarker is named the LSC17 score as it comes from the leukemia stem cells that drive disease and relapse. These dormant stem cells have properties that allow them to resist standard chemotherapy, which is designed to defeat rapidly dividing … Signature of 17 Genes Could Predict Prognosis in AML PatientsGenomeWeb |
EurekAlert (press release) |
Stem cell-based test predicts leukemia patients’ response to therapy to tailor treatment University Health Network
EurekAlert (press release) 7, 2016) – Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment. |
|
International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
Yahoo Sports 07, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced the treatment of the second patient in … |
|
Molecular Switch Finding May Help Drive Stem Cells to Desired Cell Type
Genetic Engineering & Biotechnology News Scientists at the Babraham Institute have revealed a new understanding of the molecular switches that control gene activity in human embryonic stem cells. This insight provides new avenues for improving the efficiency of being able to drive stem cells … |
Phys.Org |
Gene “bookmarking” regulates the fate of stem cells
Phys.Org A protein that stays attached on chromosomes during cell division plays a critical role in determining the type of cell that stem cells can become. The discovery, made by EPFL scientists, has significant implications for stem cell biology and their use … |
Globes |
Kadimastem soars on $7m Korean stem cell investment
Globes Corestem was founded in 2003 and deals with research, development and marketing of stem cell-based technologies in the field of cell therapy. It currently markets the ALS drug Neuronata-R. The company’s portfolio has further products for treatment of … To Lead the Field of ALS Treatment Worldwide: Kadimastem Announces Strategic Collaboration with Korean Biotech …PR Newswire (press release) |
TIME |
CRISPR Technology Scientists on Their Gene Editing Tool – Time
TIME Dr. Carl June’s lab at the University of Pennsylvania looks like any other biology research hub. There are tidy rows of black-topped workbenches flanked by … Biotech Trial of the Century Could Determine Who Owns CRISPRMIT Technology Review Brainstorm Health: The CRISPR Battle Comes to a Crispy Head …Fortune A silver lining in the CRISPR court caseMedCity News FierceBiotech –Genetic Engineering & Biotechnology News all 7 news articles » |